Abstract
Neuroblastoma in patients with congenital central hypoventilation syndrome (CCHS) as part of a neurocristopathy syndrome is a rare finding and has only been associated with paired-like homeobox 2b (PHOX2B) non-polyalanine-repeat-expansion mutations. To the best of our knowledge, we report the first case of a child with CCHS and Hirschsprung disease who had a PHOX2B polyalanine-repeat-expansion mutation (PARM) (genotype 20/33) and developed high-risk neuroblastoma. We further describe his treatment including chemotherapy and therapeutic I131-metaiodobenzylguanidine. This case highlights the need to consider neuroblastoma in patients with CCHS and the longest PHOX2B PARMs and to individualize treatment based on co-morbidities.
Original language | English (US) |
---|---|
Pages (from-to) | 2007-2010 |
Number of pages | 4 |
Journal | Pediatric Blood and Cancer |
Volume | 62 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2015 |
Keywords
- Chemotherapy
- Congenital central hypoventilation syndrome
- MIBG
- Neuroblastoma
- Neurocristopathy
- PHOX2B
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology